SuperworthLantern Pharma market cap LTRN
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Oct 23, 2026
- $8.1M
- Highest close in our data
- $237.7M
- Mar 2021
Lantern Pharma is worth $8.1M at the close on Oct 23, 2026, at $0.64 a share.
That is down 82% over the last year and down 93% over five years.
Its highest close in our data was $237.7M in Mar 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $8.1M | $8.1M | $44.9M | −79% |
| 2025 | $38.9M | $32.2M | $58.2M | +6% |
| 2024 | $36.9M | $33.2M | $114.4M | −21% |
| 2023 | $46.5M | $29.1M | $65.3M | −29% |
| 2022 | $65.6M | $46.6M | $81.3M | −27% |
| 2021 | $89.3M | $81.8M | $237.7M | −25% |
| 2020 | $119.7M | $67M | $127.5M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Lantern Pharma's size, closest first, today.
| Company | Market cap |
|---|---|
| LTRNLantern Pharma | $8.1M |
| ATNMActinium Pharmaceuticals | $47.8M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| Peer median | $64.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Lantern Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.